drugset / Trial / NCT00003712
CCI-779 in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
15 enrolled
The University of Texas Health Science Center at San Antonio
National Cancer Institute (NCI) · collabUniversity of Texas · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of CCI-779 in treating patients who have advanced solid tumors.
Timeline
- Start
- 2001-01
- Primary completion
- 2002-06
- Completion
- 2002-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temsirolimus | Small molecule | — | Intravenous |